Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Recurrent Small Cell Lung Cancer
- Relapsed Small Cell Lung Cancer
- Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04610658
- Collaborators
- Bristol-Myers Squibb
- PharmaMar
- Investigators
- Principal Investigator: Alberto A Chiappori, MD Moffitt Cancer Center
Get Well Soon